Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma

BACKGROUND: Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard therapy for cancer patients with activating BRAF mutations. However, the anti-tumorigenic effect and clinical benefit are only transient, and tumors are prone to treatment resistance and relapse. To el...

Descripción completa

Detalles Bibliográficos
Autores principales: Zecena, Helma, Tveit, Daniel, Wang, Zi, Farhat, Ahmed, Panchal, Parvita, Liu, Jing, Singh, Simar J., Sanghera, Amandeep, Bainiwal, Ajay, Teo, Shuan Y., Meyskens, Frank L., Liu-Smith, Feng, Filipp, Fabian V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883534/
https://www.ncbi.nlm.nih.gov/pubmed/29615030
http://dx.doi.org/10.1186/s12918-018-0554-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883534/
https://www.ncbi.nlm.nih.gov/pubmed/29615030
http://dx.doi.org/10.1186/s12918-018-0554-1

Ejemplares similares